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Abstract
Fe deficiency anaemia during early pregnancy has been linked with low birth weight and preterm birth. However, this evidence comes
mostly from studies measuring Hb levels rather than specific measures of Fe deficiency. The present study aimed to examine the associ-
ation between maternal Fe status during the first trimester of pregnancy, as assessed by serum ferritin, transferrin receptor and their ratio,
with size at birth and preterm birth. In the Baby VIP (Baby’s Vascular health and Iron in Pregnancy) study, we recruited 362 infants and
their mothers after delivery in Leeds, UK. Biomarkers were measured in maternal serum samples previously obtained in the first trimester
of pregnancy. The cohort included sixty-four (18 %) small for gestational age (SGA) babies. Thirty-three babies were born preterm
(9 %; between 34 and 37 weeks). First trimester maternal Fe depletion was associated with a higher risk of SGA (adjusted OR 2·2,
95 % CI 1·1, 4·1). This relationship was attenuated when including early pregnancy Hb in the model, suggesting it as a mediator (adjusted
OR 1·6, 95 % CI 0·8, 3·2). For every 10 g/l increase in maternal Hb level in the first half of pregnancy the risk of SGA was reduced by
30 % (adjusted 95 % CI 0, 40 %); levels below 110 g/l were associated with a 3-fold increase in the risk of SGA (95 % CI 1·0, 9·0). There
was no evidence of association between maternal Fe depletion and preterm birth (adjusted OR 1·5, 95 % 0·6, 3·8). The present study
shows that depleted Fe stores in early pregnancy are associated with higher risk of SGA.
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Fe deficiency (ID) is the leading single nutrient deficiency in the
world. The WHO considers it a public health condition of
epidemic proportions with significant consequences including
loss of earnings, general ill-health and premature death(1).
Anaemia, a common outcome of ID, is therefore unsurprisingly
prevalent in expectant mothers, affecting nearly half of all
pregnant women worldwide(2). Maternal Fe deficiency anaemia
(IDA) has been linked to higher risk of low birth weight, preterm
delivery and infant IDA, which in turn can permanently impair
intelligence, motor and behavioural development, and increase
risk of future IDA in the offspring(3–12).
There is a stepwise progression towards IDA: initial depletion
of Fe stores, followed by Fe deficient erythropoiesis (IDE), then
reduction in Hb concentration(13). Anaemia therefore represents
the final stage of ID; it occurs as tissue and cellular stores are
progressively exhausted; its manifestation is most readily
ascertained through assessment of Hb levels. However, non-
anaemic ID as a separate pathological entity is not well
recognised, and its association with birth outcomes is inade-
quately investigated. The prevalence of ID during pregnancy
(low serum ferritin (sF) and sparse or absent stainable Fe in
bonemarrow) isprobably far greater than theprevalenceof anae-
mia(4). ID, without anaemia, has been associated with reduced
exercise capacity, impaired temperature regulation and impaired
cognitive function in animal and human studies(14), and may
therefore implicate risks for mother and baby in pregnancy.
Studies assessing ID status require further measurements other
than Hb concentrations.
The biomarker sF is the most widely used one in this
respect. It is an indicator of body storage Fe. In women,
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levels under 15mg/l indicate depleted Fe stores(15). However,
it is affected by inflammatory conditions and therefore may
not be specific to distinguishing ID. Levels between 12 and
100mg/l are difficult to interpret because inflammation can
cause elevation of sF, even in the presence of ID(16).
Circulating serum transferrin receptor (sTfR) is a soluble form
of the membrane receptor produced by proteolytic cleavage.
Both the expression of transferrin receptor on the cell surface
and the concentration of the soluble transferrin receptor are
inversely related to the level of intracellular Fe(17). Measuring
sTfR may provide more specific information, and it has the
advantage over sF in that it can distinguish IDA from anaemia
of chronic inflammation, as well as identify Fe depletion and
functional ID in patients with concurrent inflammation(18). The
ratio of sTfR:sF ratio is considered the gold standard marker of
Fe status(19), and has been used to assess Fe status in pregnant
populations such as in the United States National Health and
Nutrition Examination Survey(20).
IDE is the most common cause of raised sTfR. Depleted Fe
stores, without IDE, is not associated with raised sTfR, and is
best indicated by low sF concentration. As ID progresses
beyond depletion of Fe stores into negative Fe status, with
inadequate Fe supply from erythropoiesis, sTfR levels begin to
rise, and continue to rise as IDE progressively worsens before
the development of anaemia. The sTfR:sF ratio quantifies the
entire spectrum of Fe status from positive Fe stores through
negative Fe balance, and is particularly useful in evaluating Fe
status in population studies(13). A close linear relationship is
demonstrable between the logarithm of the concentrations in
mg/l, of sTfR:sF ratio with body Fe as calculated from the Hb
Fe after correction for the absorption of dietary Fe(21).
The potential consequences of ID in pregnancy are signifi-
cant. Being born small for gestational age (SGA) or preterm
are both associated with short- and long-term adverse health
consequences including an increased risk of infant mortality,
as well as increased risk of cognitive dysfunction and CVD
later in life(26).
The present study therefore aimed to examine the relation-
ship between maternal Fe status assessed in early pregnancy
with size at birth and gestational age, and to investigate
whether maternal Hb level is a mediator in this relationship.
Methods
Study design
The Baby VIP (Baby’s Vascular health and Iron in Pregnancy)
study is a historical cohort study. Women aged 18 years or
over who gave birth to live offspring at the Leeds Teaching
Hospitals Trust maternity unit at a gestational age of
34 weeks or over, and had sufficient proficiency in English
to understand what is involved in study participation, give
consent and complete a written questionnaire were eligible
to be included in the study. Study exclusion criteria included
stillbirth or neonatal death, serious maternal illness, and
babies with concurrent CVD (such as patent ductus arteriosus),
inherited disorders of metabolism or congenital malformations.
Participants were approached for the study on the postnatal
wards after delivery. Each mother was asked permission to
access hers and her baby’s medical notes. The study was con-
ducted between February 2012 and January 2013. Ethical
approval was obtained from the South Yorkshire Research
Ethics Committee of the NHS National Research Ethics Service
(reference no. 11/YH/0064). All procedures were in accord-
ance with the Helsinki Declaration of 1975 as revised in
1983. Participants provided their written informed consent to
participate in the present study.
Outcome measurement
Birth weight (in g) and gestational age (in d) were ascertained
from the hospital delivery records. Customised birth weight
centiles were calculated taking into account gestational age,
maternal height, maternal pre-pregnancy or booking weight,
ethnicity, parity and neonatal sex(27). SGA was defined as
less than the tenth customised birth weight centile. Duration
of gestation was calculated from the date of the last menstrual
period, and confirmed by ultrasound scans dating at about
12 and 20 weeks gestation. Preterm birth was defined as less
than 37 þ 0 weeks gestation.
Exposure measurement
Maternal serum samples previously acquired and stored
during the first trimester of pregnancy as part of routine ante-
natal care were identified and then analysed. The biomarker
sF was measured using ELISA (Demeditec Diagnostics
GmbH) following the manufacturer’s instructions. Briefly,
10ml of plasma was treated in a sandwich ELISA method,
using fluorometric measurements and calibrated, using stan-
dards supplied by the manufacturer. Quality controls were
included as appropriate. Data were expressed in mg/l. The
WHO’s cut-off of 15mg/l in sF was used to indicate depleted
Fe stores(15). And sTfR assays were performed using a com-
mercially available kit, based on a polyclonal antibody in
a sandwich enzyme immunoassay format (DTFR1; R&D
Systems). This yielded sTfR levels in nmol/l units. The
values were converted to mg/l using a molecular weight of
sTfR of 75 000 Da (R&D technical data sheet). The sTfR:sF
ratio was obtained by dividing sTfR over sF (mg/l:mg/l). This
was logged to obtain a normal distribution.
In the UK, Hb is measured routinely in pregnancy at about
12 and 28 weeks gestation. Maternal Hb values were extracted
from the antenatal care records and/or the hospital electronic
results server. A cut-off of 110 g/l in Hb was used to indicate
anaemia at 20 weeks gestation or less, and 105 g/l to indicate
anaemia beyond 20 weeks gestation, following the National
Institute for Health and Care Excellence guidelines(28).
Covariable assessment
A basic demographic and lifestyle questionnaire was adminis-
tered to the mother by the research team at the time of
recruitment. The Index of Multiple Deprivation (IMD)
was derived from the participants’ postcodes, using the
GeoConvert tool which utilises the 2001 UK census data
N. A. Alwan et al.1986
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(http://geoconvert.mimas.ac.uk). Parity, maternal height, weight,
ethnicity, smoking, pregnancy complications (pre-eclampsia,
gestational diabetes), blood pressure measurements and intake
of Fe supplements were extracted from the mother and the
baby’s clinical records.
Statistical methods
Statistical analysis was performed using Stata version 11
(StataCorp, 2009). Univariable analysis was performed using
independent sample t test, one-way ANOVA or Mann-Whitney
test for continuous variables, and x 2 test for categorical
variables. Multivariable linear regression was performed
with customised birth weight centile and gestational age as
the main outcomes, and indicators of maternal Fe status as
predictors. Multiple logistic regression was performed with
SGA and preterm birth as binary outcomes. The models with
gestational age/preterm birth as outcomes were adjusted for
maternal covariables including age, BMI, parity, ethnicity,
smoking status, the presence of gestational diabetes or pre-
eclampsia, blood pressure at booking and 36 weeks gestation,
and IMD score. Sensitivity analyses were performed taking
into account the intake of Fe supplements during pregnancy.
Models with customised birth weight centile/SGA as outcomes
were adjusted for the variables listed above excluding
maternal ethnicity, parity and BMI which were taken into
account in the centile calculation.
Hb levels in early (#20 weeks) and late (.20 weeks) preg-
nancy were investigated as a mediator in the relationship
between maternal Fe status as expressed by sF and sTfR:sF
ratio, and birth outcomes, by adjusting for it in the relevant
models. If an association was attenuated, this could indicate
the presence of mediation(29).
For a difference in customised birth weight centile between
Fe-deficient and non-Fe deficient mothers of 10 centile points,
using a mean of 45 centile points, a standard deviation of
29(30,31), and a prevalence of ID of 25 %(32,33), a sample size
of 356 mother–baby pairs was required to achieve P ¼ 0·05
with 80 % power.
Results
In total, 362 women living in Leeds, the UK and surrounding
areas were recruited for the present study. Of them 288
(80 %) were of white ethnic origin, thirty-seven (10 %) of
Asian origin, thirteen (4 %) of African-Caribbean origin,
eleven (3 %) of mixed origin and thirteen (4 %) of other
ethnic origin. Mean maternal age was 31 (SD 6) years, and
mean maternal pre-pregnancy BMI was 26 (SD 6) kg/m2.
Among them 173 women were primiparous (40 %), and half
of the babies were male. Mean birth weight was 3329 (SD
632) g, with forty (11 %) babies weighing less than 2500 g,
and 358 women had sufficient information to derive
customised birth weight centiles. Mean customised birth
weight centile was 41 (SD 29), with sixty-four (18 %) babies
weighing less than the 10th centile (SGA), and twenty-nine
(8 %) babies weighing less than the 3rd centile. Twenty (6 %)
babies weighed more than the 90th centile. Mean gestational
age was 277 (SD 14) d i.e. 39·6 weeks. Thirty-three (9%) babies
were born preterm (all between 34 and 37 weeks gestation).
Out of 348 pregnant women with information on sF in the
first trimester, seventy-nine (23 %) had Fe depletion according
to the WHO cut-off of 15mg/l. This proportion was 46 % in
women of Asian origin compared to 20 % in women of
white origin. Median sF was 13·7mg/l (interquartile range
16·9–62·4). Mean maternal Hb was 126 g/l and 116 g/l (SD 10)
in the first and second halves of pregnancy respectively.
Prevalence of anaemia at #20 weeks (Hb ,110 g/l) and
.20 weeks gestation (Hb ,105 g/l) was 5 % (16/329) and
14 % (48/337) respectively. Only half of anaemic women in
the first half (n 8), and 45 % of anaemic women in the
second half of pregnancy (n 22), had a first trimester sF of
less than 15mg/l. However, fourteen (89 %) of anaemic
women in the first half of pregnancy and forty-three (90 %)
of anaemic women in the second half of pregnancy had sF
of less than 70mg/l.
Also 121 women (34 %) took Fe supplements at some stage
during pregnancy. Eight (2 %) started taking them in the first
trimester, compared to sixty-seven (18·6 %) who did so in
the second trimester, and forty-six (13 %) in the third trimester.
Out of those with Fe depletion in the first trimester
(sF ,15mg/l), only forty-six (58 %) had Fe supplements
during their pregnancy, compared to thirteen (81 %) of
anaemic women in the first half of pregnancy, and forty
(83 %) of anaemic women in the second half of pregnancy.
Women with SGA babies were more likely to smoke, have
lower early pregnancy Hb, be anaemic at #20 weeks ges-
tation, have Fe depletion in the first trimester (sF ,15mg/l)
and have suffered from pre-eclampsia during pregnancy, com-
pared to women with babies who were not SGA. In women
with Fe depletion in the first trimester of pregnancy, 25 %
had SGA babies compared with 14 % of women with no Fe
depletion. Table 1 describes the characteristics of participants
whose babies were born SGA compared to those with babies
who were not SGA.
There was no evidence of an association between maternal
sF, sTfR, log sTfR:sF ratio with customised birth weight centile.
In univariable analysis, maternal anaemia in early pregnancy
was associated with reduction of 15 centile points in birth
weight (95 % CI 1, 29; P¼0·04). However, this association
was attenuated when adjusting for maternal age, smoking,
gestational diabetes, pre-eclampsia and IMD (adjusted differ-
ence in customised birth weight centile ¼ -11 centile points,
95 % CI -25, 3; P¼0·1) (Table 2).
Maternal Fe depletion in the first trimester (sF ,15mg/l)
was associated with a higher risk of a SGA baby (adjusted
OR 2·2, 95 % CI 1·1, 4·1; P¼0·02). Adjusting for maternal Fe
supplement intake in a sensitivity analysis did not alter this
association (adjusted OR 2·3, 95 % CI 1·2, 4·5; P¼0·02). How-
ever, this relationship was attenuated when including early
pregnancy Hb in the model (adjusted OR 1·6, 95 % CI 0·8,
3·2; P¼0·2). For every 10 g/l increase in maternal Hb level in
the first half of pregnancy the risk of SGA was reduced by
30% (adjusted 95% CI 0, 40%; P¼0·03), with levels ,110 g/l
associated with 3-fold increase in the risk of SGA (95 % CI
1·0, 9·0; P¼0·05). Maternal sTfR was also associated in the
Maternal iron deficiency and birth weight 1987
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multivariable model adjusting for maternal age, smoking,
gestational diabetes, pre-eclampsia and IMD with SGA
(adjusted OR 1·1 for every 1 nmol/l increase in sTfR, 95 % CI
1·0,1·1; P¼0·04). However, there was no evidence of associ-
ation of SGA with maternal sTfR:sF ratio (Table 3).
There was no evidence of association between maternal Fe
status measured by sF, sTfR or log sTfR:sF ratio with preterm
birth or gestational age. However, there was an association
observed between early pregnancy maternal Hb and gesta-
tional age in univariable analysis. For every 10 g/l increase
in early pregnancy Hb, there was an increase in gestational
age by 2 d (95 % CI 0·2, 3·0; P¼0·03). This association was atte-
nuated in the multivariable model adjusting for maternal age,
ethnicity, parity, pre-pregnancy BMI, smoking, gestational
Table 2. Associations of customised birth weight centile with indicators of iron status during pregnancy in the Baby’s Vascular health and Iron in
Pregnancy study
(Differences and 95 % confidence intervals)
Difference in birth weight centile mean*
Predictor
Unadjusted
difference
95 % CI for
unadjusted
difference P
Adjusted
difference†
95 % CI for
adjusted
difference P
n (multivariable
model)
Maternal sF at 12 weeks gestation (per 10mg/l change) 20·1 21·0, 0·6 0·9 0·1 20·6, 0·7 0·9 341
Maternal Fe depletion at 12 weeks gestation (sF ,15mg/l) 24·2 211·3, 2·3 0·3 24·6 211·7, 2·5 0·2 341
Maternal sTfR at 12 weeks gestation (per nmol/l) 20·2 20·7, 0·4 0·5 20·3 20·8, 0·3 0·3 341
Maternal log sTfR:sF ratio at 12 weeks gestation (per mg/l) 20·8 23·4, 1·7 0·5 21·2 23·8, 1·3 0·3 341
Maternal Hb at #20 weeks gestation (per 10 g/l) 1·4 21·7, 4·5 0·4 1·0 22·0, 4·1 0·6 326
Maternal Hb at .20 weeks gestation (per 10 g/l) 20·8 23·7, 2·2 0·6 21·2 24·4, 1·4 0·3 334
Maternal anaemia at #20 weeks gestation (,110 g/l) 215·0 229·2, 21·0 0·04 211·2 225·4, 3·1 0·1 326
Maternal anaemia at .20 weeks gestation (,105 g/l) 24·5 213·1, 4·2 0·3 21·4 210·1, 7·3 0·8 334
sF, serum ferritin; sTfR, serum transferrin receptor.
* Customised birth weight centile (takes into account maternal pre-pregnancy weight, height, ethnicity, parity, gestational age and baby’s sex).
† Adjusted for maternal age, smoking, gestational diabetes, pre-eclampsia and area deprivation score (Index of Multiple Deprivation).
Table 1. Characteristics of Baby’s Vascular health and Iron in Pregnancy study participants (n 362) by size at birth
(Mean values and standard deviations; median values and interquartile ranges (IQR); percentages and 95 %
confidence intervals)
SGA (n 64)* Not SGA (n 294)
Mean SD Mean SD P†
Maternal age at antenatal booking (years) 30·4 6·0 30·5 5·7 0·8
Maternal BMI at antenatal booking (kg/m2) 25·7 5·8 26·3 5·8 0·4
Maternal Hb at #20 weeks gestation (g/l) 123 11 127 10 0·02
Maternal Hb at .20 weeks gestation (g/l) 116 11 116 10 0·9
IMD 30·6 19·2 29·2 19·8 0·6
Gestational age (d) 270 15 279 13 ,0·0001
Birth weight (g) 2499 446 3510 516 ,0·0001
First trimester maternal sF (mg/l) 0·8
Median 33·5 30·7
IQR 12·4–52·5 17·9–65·7
First trimester maternal sTfR (nmol/l) 0·1
Median 13·6 12·5
IQR 10·0–17·9 10·3–16·0
First trimester maternal sF:sTfR ratio (mg/l) 0·6
Median 38·1 28·0
IQR 16·4–101·2 14·4–61·2
% 95 % CI % 95 % CI
Primiparous 41 29, 54 49 44, 55 0·2
Maternal smoking at antenatal booking 22 13, 35 12 9, 17 0·04
Maternal White ethnicity 75 63, 85 81 76, 85 0·3
Maternal Asian ethnicity 16 8, 27 9 6, 13 -
Maternal African Caribbean ethnicity 3 0, 11 3 1, 6 -
Anaemia at #20 weeks gestation (,110 g/l) 11 4, 23 4 2, 7 0·02
Anaemia at .20 weeks gestation (,105 g/l) 15 6, 27 14 10, 19 0·9
Gestational diabetes 3 0, 11 1 0, 3 0·3
Pre-eclampsia 5 1, 13 1 0, 3 0·04
Male baby 45 33, 58 51 46, 57 0·4
Preterm birth (34–37 weeks gestation) 19 10, 31 7 5, 11 0·004
SGA, small for gestational age; IMD, Index of Multiple Deprivation; sF, serum ferritin; sTfR, serum transferrin receptor.
*,10th birth weight centile.
† Independent samples t test or Mann-Whitney test for continuous variables, and x 2 test for categorical variables.
N. A. Alwan et al.1988
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diabetes, pre-eclampsia and IMD score. Mothers who were
anaemic in the first half of pregnancy had on average a
gestation shorter by 7 d (adjusted 95 % CI 0, 14; P¼0·05) com-
pared to non-anaemic mothers (Tables 4 and 5).
Discussion
The present study in an inner city population sample of women,
with about 20 % from ethnic minority background, shows that
maternal Fe depletion in early pregnancy was associated with
a greater odd of an SGA birth. This relationship appeared
to be mediated by early pregnancy maternal Hb, which was
independently and inversely associated with SGA.
Interpretation of results
In the present study, anaemia in the first half of pregnancy
was associated with a higher risk of having a baby who is
SGA, and every 10 g/l increase in early pregnancy maternal
Hb (before 20 weeks gestation) was associated with a 30 %
reduction in the risk of SGA. This result supports the previous
evidence of association between early maternal Hb and
anaemia with the risk of low birth weight(34,35).
As it was previously demonstrated(36), maternal Hb in the
second half of pregnancy was not associated with SGA in
the present study as well. In contrast, a previous study from
our group, conducted 10 years earlier, found a 40 % increase
in the risk of SGA with every 10 g/l increase in maternal Hb
at 28 weeks gestation in a sample size of 572 women(37).
Although the proportion of participants with late pregnancy
anaemia in that study (23 %) was higher than the proportion
observed in the present study (14 %), mean Hb in both studies
was similar. Why the results are different is not obvious, but
may be related to the time course of plasma volume expan-
sion in the different populations.
There was no evidence of association between the inci-
dence of preterm birth and early pregnancy maternal Hb or
anaemia in the present study contrary to the findings of
previous studies(38–40). However, maternal anaemia in the
first half of pregnancy was marginally associated with a
reduction in gestational age, when analysed as a continuous
outcome, while maternal anaemia in the second half of
pregnancy was marginally associated with a reduction in the
risk of preterm birth.
The evidence available in the literature of the association
between maternal anaemia and birth outcomes suggests that
Table 3. Associations of being born small for gestational age with indicators of iron status during pregnancy in the Baby’s Vascular health and Iron in
Pregnancy study
(Odds ratios and 95 % confidence intervals)
OR of SGA*
Predictor
Unadjusted
OR
95 % CI for
unadjusted OR P
Adjusted
OR†
95 % CI for
adjusted OR P
n (multivariable
model)
Maternal sF at 12 weeks gestation (mg/l) 1·0 0·9, 1·0 0·8 1·0 0·9, 1·0 0·7 341
Maternal Fe depletion at 12 weeks gestation (sF ,15mg/l) 2·0 1·1, 3·7 0·02 2·2 1·1, 4·1 0·02 341
Maternal sTfR at 12 weeks gestation (nmol/l) 1·0 1·0, 1·1 0·1 1·1 1·0, 1·1 0·04 341
Maternal log sTfR:sF ratio at 12 weeks gestation (mg/l) 1·1 0·9, 1·4 0·3 1·2 0·9, 1·5 0·1 341
Maternal Hb at #20 weeks gestation (per 10 g/l) 0·7 0·6, 1·0 0·03 0·7 0·6, 1·0 0·03 326
Maternal Hb at .20 weeks gestation (per 10 g/l) 1·0 0·7, 1·3 0·9 1·1 0·8, 1·4 0·7 334
Maternal anaemia at #20 weeks gestation (,110 g/l) 3·3 1·1, 9·4 0·03 3·0 1·0, 9·0 0·05 326
Maternal anaemia at .20 weeks gestation (,105 g/l) 1·0 0·5, 2·3 0·9 0·8 0·4, 2·0 0·7 334
SGA, small for gestational age; sF, serum ferritin; sTfR, serum transferrin receptor.
*,10th customised birth weight centile (takes into account maternal pre-pregnancy weight, height, ethnicity, parity, gestational age and baby’s sex).
† Adjusted for maternal age, smoking, gestational diabetes, pre-eclampsia, and area deprivation score (Index of Multiple Deprivation).
Table 4. Associations of gestational age with indicators of iron status during pregnancy in the Baby’s Vascular health and Iron in Pregnancy study
(Differences and 95 % confidence intervals)
Difference in gestational age mean (d)
Predictor
Unadjusted
difference
95 % CI for
unadjusted
difference P
Adjusted
difference*
95 % CI for
adjusted
difference P
n (multivariable
model)
Maternal sF at 12 weeks gestation (per 10mg/l change) 0·1 20·2, 0·4 0·6 20·2 20·4, 0·2 0·6 341
Maternal Fe depletion at 12 weeks gestation (sF ,15mg/l) 0·3 23·4, 4·0 0·9 0·02 23·4, 3·4 0·9 341
Maternal sTfR at 12 weeks gestation (nmol/l) 20·1 20·2, 0·2 0·5 20·1 20·3, 0·2 0·5 341
Maternal log sTfR:sF ratio at 12 weeks gestation (mg/l) 20·6 21·8, 0·6 0·3 0·01 21·2, 1·3 0·9 341
Maternal Hb at #20 weeks gestation (per 10 g/l) 1·6 0·2, 3·0 0·03 1·1 20·4, 2·6 0·1 326
Maternal Hb at .20 weeks gestation (per 10 g/l) 0·1 21·3, 1·5 0·9 20·5 21·9, 0·9 0·5 334
Maternal anaemia at #20 weeks gestation (,110 g/l) 29·1 215·8, 22·4 0·008 26·8 213·6, 0·1 0·05 326
Maternal anaemia at .20 weeks gestation (,105 g/l) 1·6 22·4, 5·6 0·4 3·7 20·4, 7·8 0·07 334
sF, serum ferritin; sTfR, serum transferrin receptor.
* Adjusted for maternal age, pre-pregnancy BMI, ethnicity, parity, smoking, gestational diabetes, pre-eclampsia, and area deprivation score (Index of Multiple Deprivation).
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it is U-shaped(41). Causes of adverse birth outcomes may differ
at the extremes of the maternal Hb range. While low Hb in
early pregnancy may reflect ID or other nutritional
deficiencies such as vitamin B or folic acid, high Hb values
later in pregnancy may reflect inadequate expansion of
plasma volume. Rasmussen(41) suggests that this U-shaped
association is spurious due to the design of research evidence
available; it is more apparent in studies that use ‘lowest Hb’
than in those that control for the stage of gestation, or include
data only from women very early in pregnancy, when changes
in plasma volume are minimal(11,38).
Participants in the present study who were Fe-depleted at
the beginning of pregnancy were twice as likely to have
SGA babies, compared to those who were Fe-replete. Maternal
sTfR level measured in the first trimester of pregnancy (which
increases in ID) was also marginally associated with higher
risk of SGA. These results are consistent with findings from
previous studies(42).
The relationship between maternal Fe depletion in the first
trimester and SGA was tested for mediation by maternal Hb, as
it was an independent predictor of SGA. Including maternal
Hb in the model attenuated the relationship between maternal
Fe depletion and SGA. This may point to the possibility that
the mechanism through which inadequate body Fe could
potentially result in small size at birth is through the efficiency
of carrying oxygen to the placenta, which is reduced by a
reduction in maternal Hb concentrations. In animal models
IDA also increases oxidative stress levels in the liver, heart,
kidney and placenta, as well as hypoxia and inflammation
in placenta(43). On the other hand, there could be another
pathway of association between anaemia in pregnancy and
adverse offspring outcomes other than ID, such as other
nutrient deficiencies.
A major problem in interpreting Hb values and how they
relate to maternal Fe status is the physiological process of
plasma volume expansion in pregnancy. This leads to a fall
in Hb level which obscures the typical relationship between
Fe status and Hb levels. Not only that, it also makes it difficult
to interpret plasma-based indicators of Fe depletion including
sF due to plasma dilution. Also, the point at which Hb is
assessed is of utmost importance, as plasma volume and cell
mass change in the different stages of pregnancy(41).
Therefore, assessing Hb in early pregnancy, before the mate-
rialisation of plasma expansion, reflects Fe status better than
later in pregnancy.
Strengths and limitations
Birth weight was ascertained objectively from the medical
birth records. Gestational age was calculated using infor-
mation from a dating ultrasound scan at the end of the first
trimester of pregnancy and extracted from the medical
records. Therefore, these two outcome measures were not
subject to measurement bias. We have adjusted the main
study outcome for maternal weight, height, ethnicity, parity
as well as baby’s sex and gestational age using the GROW-
centile calculator, which has been recommended by the UK
Royal College of Obstetrics and Gynaecology for assessment
of birth weight(44). We have also adjusted the statistical models
for a measure of deprivation, the IMD, however, it is worth
noting that this is an area-based rather than an individual-based
measure.
The present study assessed the exposure of interest
prospectively, as the maternal serum samples were collected
in the first trimester of pregnancy. Information on maternal
Hb and Fe supplements was ascertained objectively from the
medical records, rather than by self-reporting. The best
available measure, which utilised the ferritin and transferrin
receptor biomarkers in a ratio that relates directly to total
body Fe stores, was used to assess maternal Fe status(19).
A study set out to determine the diagnostic value of sTfR:sF
ratio to determine body Fe stores against bone marrow
aspirate examination showed that sTfR:sF ratio had the best
diagnostic efficiency with the sensitivity of 81 % and a speci-
ficity of 97 %. And sF alone, with a cut-off of 60mg/l, had
the same specificity but lower sensitivity (76 %)(45).
Deriving body Fe stores estimates from sTfR:sF ratio is
limited by the current availability of several commercial
assays that yield different sTfR values. The calculation formula
provided by Cook(46) used to deduct body Fe stores values
can only be used if sTfR assay commutability is established.
Furthermore, the calculation is complicated by different
Table 5. Associations of being born preterm with indicators of iron status during pregnancy in the Baby’s Vascular health and Iron in Pregnancy study
(Odds ratios and 95 % confidence intervals)
OR of preterm birth (,37 weeks gestation)
Predictor
Unadjusted
OR
95 % CI
of unadjusted
OR P
Adjusted
OR*
95 % CI
of adjusted
OR P
n (multivariable
model)
Maternal sF at 12 weeks gestation (mg/l) 1·0 0·9, 1·0 0·6 1·0 0·9, 1·0 0·6 341
Maternal Fe depletion at 12 weeks gestation (sF ,15mg/l) 1·6 0·7, 3·7 0·3 1·5 0·6, 3·8 0·4 341
Maternal sTfR at 12 weeks gestation (nmol/l) 1·0 1·0, 1·1 0·5 1·0 1·0, 1·1 0·5 341
Maternal log sTfR:sF ratio at 12 weeks gestation (mg/l) 1·1 0·8, 1·4 0·8 1·0 0·7, 1·5 0·8 341
Maternal Hb at #20 weeks gestation (per 10 g/l) 0·8 0·6, 1·1 0·2 0·9 0·6, 1·4 0·7 326
Maternal Hb at .20 weeks gestation (per 10 g/l) 1·2 0·8, 1·7 0·5 1·3 0·9, 1·9 0·2 334
Maternal anaemia at #20 weeks gestation (,110 g/l) 2·6 0·7, 9·5 0·2 1·3 0·3, 6·2 0·8 326
Maternal anaemia at .20 weeks gestation (,105 g/l) 0·4 0·1, 1,9 0·3 0·2 0·04, 1·0 0·05 334
sF, serum ferritin; sTfR, serum transferrin receptor.
* Adjusted for maternal age, pre-pregnancy BMI, ethnicity, parity, smoking, gestational diabetes, pre-eclampsia, and area deprivation score (Index of Multiple Deprivation).
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inflammatory responses in pregnancy, which may affect ferri-
tin values. There is a pressing need to calibrate sTfR assays
against international reference standards to provide compar-
ability across studies.
Implications for research and practice
Currently in the UK, routine Fe supplementation is not rec-
ommended in pregnancy. Pregnant women are only screened
for anaemia which is at the extreme end of ID spectrum.
Screening for ID in women at an early stage in pregnancy
may be beneficial, since it has been shown in the present
study and other research that it may predict adverse birth out-
comes including SGA. Correcting ID may mitigate or prevent
this outcome. The ideal way to ascertain ID would be to test
sF levels in the first trimester of pregnancy, preferably at the
first antenatal booking visit. If sF was low, indicating ID
based on international cut-off values, then Fe supplementation
may be recommended plus dietary advice to increase intake
from diet and maximise absorption of both non-haem Fe
and supplements. The issue of the side effects of supplements,
and optimisation of their absorption must be addressed with
women who are deemed in need of them.
Research is needed to assess the cost-effectiveness of such a
routine testing and selective supplementation approach on a
population level, taking into account country-specific preva-
lence rates of SGA and ID in women of childbearing age.
Until that time, as part of routine antenatal care, emphasis
should be on receiving more detailed and helpful dietary
advice and ways to optimise nutritional status in pregnancy,
including Fe intake and absorption from the diet. This could
be delivered in a personalised fashion as part of the antenatal
care package rather than mere signposting to leaflets
and information websites. Incorporating dietary advice and
follow-up in routine antenatal care is likely to have cost
implications. Therefore, careful evaluation of the clinical and
cost-effectiveness of such a personalised approach should
be planned and conducted.
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the Baby VIP study. Our sincere thanks go to Julie Grindey,
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